News | December 30, 2025
Astal signs LoI with Immuna Therapeutics
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
The partnership also sets the stage for broader collaboration on rare disease treatments
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The study met its primary endpoint with flying colors
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Harbour BioMed brings advanced antibody discovery platforms to the table
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Subscribe To Our Newsletter & Stay Updated
